A study presented by researchers at Fox Chase Cancer Center shows that some patients with metastatic kidney cancer receiving a combination therapy can safely stop or pause treatment after two years if they have a good response.
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).
